Vol. 3 No. 2 (2023)
Reimbursement Reviews

Pitolisant Hydrochloride (Wakix)

Published February 22, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Pitolisant hydrochloride (Wakix), up to 40 mg daily, 5 mg and 20 mg tablets, oral.
  • Indication: Treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy.